Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous platelet-rich fibrin glue
- Development stage
- Phase 1
- Lead developer
- Jinling Hospital
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
Autologous platelet-rich fibrin glue (PRFG) is a biologic therapy prepared from a patient's own blood, containing concentrated fibrinogen, factor XIII, thrombin, calcium, platelets, and leukocytes. It is used as a surgical sealant to treat low-output enterocutaneous fistulas (ECFs). When applied to the fistula tract, it forms a coagulum that mechanically seals the tract and releases growth factors from platelets to promote tissue healing and fistula closure. Jinling Hospital in China has led multi-center clinical trials evaluating its efficacy compared to commercial porcine-derived fibrin glue and standard drainage cessation.
- Other names
- autologous fibrin glueplatelet-rich fibrin glueautologous PRFG
Beyond the preview
Go deeper on autologous platelet-rich fibrin glue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous platelet-rich fibrin glue.